Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Aug 16;83(5):573–576. doi: 10.1054/bjoc.2000.1304

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer

G D Beretta 1, G Michetti 2, M O Belometti 2, G Gritti 3, A Quadri 1, P Poletti 1, R Labianca 1
PMCID: PMC2363520  PMID: 10944594

Abstract

Cisplatin-based combinations are efficacious in increasing the overall survival of patients with non-small cell lung cancer (NSCLC), but their toxicity makes them unsuitable for elderly and unfit patients. The primary objective of this non-randomized phase II study was to evaluate the feasibility and activity of the gemcitabine plus vinorelbine combination in previously untreated elderly and/or unfit patients with measurable stage III or IV NSCLC. Forty-three patients aged ≥ 65 years or with contraindications against cisplatin treatment (36 males and seven females: median age 66 years; range 48–75: PS 0 = 11, PS 1 = 19, PS 2 = 13) received intravenous (i.v.) gemcitabine 1000 mg m–2, followed by vinorelbine 25 mg m–2i.v. on day 1 and 8 every 21 days. Fifteen patients (34.9%) achieved partial remission (confidence interval: 27.6–42.2%) for a median duration of 6 months; the median survival of these patients has not yet been reached. A further 15 had stable disease for a median of 4 months and a median survival of 7 months. The 10 patients (23.2%) who experienced disease progression had a median survival of 4 months. Three patients are not evaluable. The 1-year actuarial survival rate is 31.1%. The treatment was well tolerated: only 35% of the patients had grade 3 or 4 granulocytopenia on day 14, none experienced episodes of neutropenic fever, and there was no evidence of severe haematological toxicity upon recycling. Only 9% of the patients suffered from gastrointestinal toxicity (grade 3); increased but reversible transaminase levels were observed in 11.6%. In conclusion, the results of this phase II study show that the combination of gemcitabine and vinorelbine is active and well tolerated in NSCLC, and thus encourage its use in elderly or unfit patients. © 2000 Cancer Research Campaign

Keywords: elderly patients, unfit patients, NSCLC, gemcitabine, vinorelbine

Full Text

The Full Text of this article is available as a PDF (56.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonomi P. Review of paclitaxel/carboplatin in advanced non-small cell lung cancer. Semin Oncol. 1999 Feb;26(1 Suppl 2):55–59. [PubMed] [Google Scholar]
  2. Fossella F. V., Lee J. S., Shin D. M., Calayag M., Huber M., Perez-Soler R., Murphy W. K., Lippman S., Benner S., Glisson B. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 1995 Mar;13(3):645–651. doi: 10.1200/JCO.1995.13.3.645. [DOI] [PubMed] [Google Scholar]
  3. Frasci G., Panza N., Comella P., Nicolella G. P., Natale M., Pacilio C., Gravina A., Caputi V., Botti G., Comella G. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study. Ann Oncol. 1997 Oct;8(10):1045–1048. doi: 10.1023/a:1008218306355. [DOI] [PubMed] [Google Scholar]
  4. Fukuoka M., Niitani H., Suzuki A., Motomiya M., Hasegawa K., Nishiwaki Y., Kuriyama T., Ariyoshi Y., Negoro S., Masuda N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992 Jan;10(1):16–20. doi: 10.1200/JCO.1992.10.1.16. [DOI] [PubMed] [Google Scholar]
  5. Goss G. D., Logan D. M., Newman T. E., Evans W. K. Use of vinorelbine in non-small-cell lung cancer. Provincial Lung Disease Site Group. Cancer Prev Control. 1997;1(1):28–38. [PubMed] [Google Scholar]
  6. Isokangas O. P., Knuuttila A., Halme M., Mäntylä M., Lindström I., Nikkanen V., Viren M., Joensuu H., Mattson K. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann Oncol. 1999 Sep;10(9):1059–1063. doi: 10.1023/a:1008305017829. [DOI] [PubMed] [Google Scholar]
  7. Klastersky J., Sculier J. P., Lacroix H., Dabouis G., Bureau G., Libert P., Richez M., Ravez P., Vandermoten G., Thiriaux J. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556–1562. doi: 10.1200/JCO.1990.8.9.1556. [DOI] [PubMed] [Google Scholar]
  8. Langer C. J., Leighton J. C., Comis R. L., O'Dwyer P. J., McAleer C. A., Bonjo C. A., Engstrom P. F., Litwin S., Ozols R. F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995 Aug;13(8):1860–1870. doi: 10.1200/JCO.1995.13.8.1860. [DOI] [PubMed] [Google Scholar]
  9. Le Chevalier T. Chimiothérapie des cancers bronchiques non à petites cellules. Presse Med. 1996 Nov 16;25(35):1699–1703. [PubMed] [Google Scholar]
  10. Lilenbaum R. C., Green M. R. Multimodality therapy for non-small-cell lung cancer. Oncology (Williston Park) 1994 May;8(5):25-31; discussion 32, 35-6. [PubMed] [Google Scholar]
  11. Lilenbaum R. C., Green M. R. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol. 1993 Jul;11(7):1391–1402. doi: 10.1200/JCO.1993.11.7.1391. [DOI] [PubMed] [Google Scholar]
  12. Lorusso V., Carpagnano F., Frasci G., Panza N., Di Rienzo G., Cisternino M. L., Napoli G., Orlando S., Cinieri S., Brunetti C. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol. 2000 Jan;18(2):405–411. doi: 10.1200/JCO.2000.18.2.405. [DOI] [PubMed] [Google Scholar]
  13. Noble S., Goa K. L. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997 Sep;54(3):447–472. doi: 10.2165/00003495-199754030-00009. [DOI] [PubMed] [Google Scholar]
  14. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  15. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1–10. doi: 10.1016/0197-2456(89)90015-9. [DOI] [PubMed] [Google Scholar]
  16. Souquet P. J., Chauvin F., Boissel J. P., Cellerino R., Cormier Y., Ganz P. A., Kaasa S., Pater J. L., Quoix E., Rapp E. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993 Jul 3;342(8862):19–21. doi: 10.1016/0140-6736(93)91882-m. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES